Could a cancer drug slow MS progression? new trial halted midway

NCT ID NCT05441488

Terminated Disease control Sponsor: AB Science Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether the oral drug masitinib can slow disability worsening in people with progressive multiple sclerosis who do not have relapses. About 800 participants will receive either masitinib or a placebo for 96 weeks. The main goal is to see if masitinib delays confirmed disability progression. The study is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: masitinib
What this could lead to: If successful, masitinib could offer a new oral option to slow disability progression in people with progressive multiple sclerosis who have no relapses.
What could go wrong: This trial is currently suspended, and it is a single phase 3 study. Masitinib may not prove more effective than placebo, and side effects could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis primary progressive multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROGRESSIVE MULTIPLE SCLEROSIS

Contacts and locations

Locations

AHEPA University Hospital, Aristotle University of Thessaloniki

Thessaloniki, Greece
Athens Naval Hospital

Athens, Greece
Azienda Ospedaliero Universitaria Policlinico "G.Rodolico -San Marco"

Catania, Italy
Centre Hospitalier Universitaire Nimes - Service de Neurologie

Nîmes, France
Centre Hospitalier Universitaire Toulouse

Toulouse, France
Centre Hospitalier Universitaire de Rouen

Rouen, France
Centre Hospitalier Universitaire de Strasbourg

Strasbourg, France
Centre hospitalier intercommunal de Poissy-Saint-Germain-en-Laye

Poissy, France
Centrum Neurologii Krzysztof Selmaj

Lodz, Poland
Centrum för neurologi

Stockholm, Sweden
City Hospital No. 40 Kurortny District

Saint Petersburg, Russia
Clinical Best Solutions

Warsaw, Poland
Communal Non-Profit Enterprise "Ternopil Regional Clinical Psychoneurological Hospital" of Ternopil Regional Council, Department of Neurology #1

Ternopil, Ukraine
Eginition Hospital, Athens University Medical School

Athens, Greece
General University Hospital of Larissa

Larissa, Greece
Generała Jarosława Dąbrowskiego

Oświęcim, Poland
Gregorio Marañón General University Hospital

Madrid, Spain
Hospital Clínico San Carlos

Madrid, Spain
Hospital Universitario de Cruces

Bilbao, Spain
Hospital Universitario y Politécnico La Fe

Valencia, Spain
Hospital del Mar

Barcelona, Spain
Hôpital Pasteur - CHU de Nice

Nice, France
Hôpital Roger Salengro

Lille, France
LLC "Center of socially significant diseases"

Saint Petersburg, Russia
Le Centre hospitalier universitaire de Poitiers

Poitiers, France
Lviv Regional Clinical Hospital

Lviv, Ukraine
NOVI-MED

Ksawerów, Poland
NZOZ Neuro-Kard

Poznan, Poland
NZOZ Neuro-Med

Lublin, Poland
Nzoz Neuro-Medic

Katowice, Poland
Perm Regional Clinical Hospital

Perm, Russia
Private Clinic ELPIS

Volos, Greece
Rivne Regional Specialized Dispensary for Radiation Protection of the Population Municipal Enterprise

Rivne, Ukraine
Sahlgrenska University Hospital

Gothenburg, Sweden
Salutem Medical Center

Vinnytsia, Ukraine
Service de Neurologie Hôpital Henri-Mondor

Créteil, France
State Budgetary Institution of Health of the City of Moscow City Polyclinic #2

Moscow, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.